Skip to main content
TipRanks
Go Ultimate75% OFF

Solara Active Pharma Sciences Ltd. (SOLARA) AI Stock Analysis

3 Followers
IN:SOLARA

Solara Active Pharma Sciences Ltd.

(NSE:SOLARA)

Select Model
Rating:50Neutral
Price Target:INR 629.00â–¼(-1.61% Downside)
Action:reiterated
Date:09/08/26

The overall score is constrained by very weak fundamentals. The company's financial performance and valuation are both scored at the minimum of 37, driven by persistent net losses, volatile cash flows, and a negative P/E ratio. These significant risks are partially offset by strong technical momentum, with the stock trading above all key moving averages and showing bullish MACD and RSI signals. The balance sheet's moderate leverage provides a slight cushion, but the core issue of unprofitability remains the dominant factor.

Positive Factors
Revenue RecoveryRevenue returning to growth after a flat FY2025 indicates renewed commercial activity. The 13.5% FY2026 increase expands the base from which Solara can rebuild earnings and supports its API manufacturing business over the medium term.
Negative Factors
Persistent Net LossSolara remains loss-making at the net-income level despite returning to positive operating profit. This limits internally generated equity growth, weakens shareholder returns, and indicates that the recovery in operating performance has not yet translated into durable bottom-line profitability.

Solara Active Pharma Sciences Ltd. (SOLARA) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%IN:SOLARA+22.39%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 30.96B
Dividend Yield
―
Average Volume (3M)
27.48K
Price to Earnings (P/E)
84.3
Beta (1Y)
0.69
Revenue Growth
27.30%
EPS Growth
456.80%
Country
India
Employees
1,669
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Solara Active Pharma Sciences Ltd. Business Overview & Revenue Model

Company Description

Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, pr...

How the Company Makes Money

Solara makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) to pharmaceutical companies that formulate and commercialize finished drug products. Revenue is generated from (1) API sales, where Solara supplies spe...

Solara Active Pharma Sciences Ltd. Financial Statement Overview

Summary

Financial performance is weak. The Income Statement (Score 28) shows persistent net losses and volatile margins, the Cash Flow Statement (Score 26) reveals inconsistent and declining cash generation with low debt coverage, and the Balance Sheet (Score 42) is the only relative bright spot with manageable leverage. The overall financial health is poor, driven by a lack of consistent profitability and weak cash flows.

Income Statement

28Negative

Balance Sheet

42Neutral

Cash Flow

26Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue15.35B13.69B12.84B12.89B14.27B12.68B
Gross Profit4.12B3.66B6.57B-1.30B1.25B5.60B
EBITDA2.35B1.87B2.06B-2.82B1.53B863.30M
Net Income369.40M-74.10M5.40M-5.67B-221.70M-581.50M
Balance Sheet
Total Assets24.54B23.33B22.32B23.51B28.99B29.53B
Cash, Cash Equivalents and Short-Term Investments709.10M533.40M41.10M84.40M87.30M463.80M
Total Debt5.91B6.87B7.96B10.12B10.13B10.37B
Total Liabilities10.15B10.77B11.35B14.14B13.97B14.18B
Stockholders Equity14.36B12.53B10.94B9.34B15.00B15.25B
Cash Flow
Free Cash Flow088.80M1.73B678.10M449.40M-4.51B
Operating Cash Flow0617.00M2.13B1.09B1.56B-2.42B
Investing Cash Flow0-998.60M-368.30M-35.10M-811.40M-2.43B
Financing Cash Flow0386.90M-1.80B-1.06B-1.13B3.34B

Solara Active Pharma Sciences Ltd. Technical Analysis

Technical Analysis SentimentNeutral
Last Price639.30

Price Trends

50DMA678.43Negative
100DMA619.11Positive
200DMA561.67Positive

Market Momentum

MACD-0.91Negative
RSI48.86Neutral
STOCH29.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SOLARA, the sentiment is Neutral. The current price of 639.30 is below the 20-day moving average (MA) of 645.62, below the 50-day MA of 678.43, and above the 200-day MA of 561.67, indicating a neutral trend. The MACD of -0.91 indicates Negative momentum. The RSI at 48.86 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SOLARA.

Solara Active Pharma Sciences Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:SOLARA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:STARIN:STAR77OutperformINR 88.32B14.32―0.52%11.28%55.18%
IN:IOLCPIN:IOLCP72OutperformINR 55.74B27.42―0.53%26.76%75.41%
IN:GRANULESIN:GRANULES59NeutralINR 202.31B27.59―0.22%21.75%36.70%
IN:HIKALIN:HIKAL57NeutralINR 27.54B-557.88―0.27%8.93%-149.51%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:UNICHEMLABIN:UNICHEMLAB51NeutralINR 34.01B9.95――6.44%283.10%
IN:SOLARAIN:SOLARA50NeutralINR 32.01B84.26――27.30%456.80%

* Healthcare Sector Average

Performance Comparison

0%50%100%IN:SOLARAIN:GRANULESIN:HIKALIN:IOLCPIN:STARIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SOLARA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SOLARASolara Active Pharma Sciences Ltd.639.3093.1017.05%
IN:GRANULESGranules India Limited804.40262.0848.33%
IN:HIKALHikal Limited221.85-2.66-1.19%
IN:IOLCPIOL Chemicals & Pharmaceuticals Ltd.191.70102.60115.15%
IN:STARStrides Pharma Science Ltd972.6582.279.24%
IN:UNICHEMLABUnichem Laboratories Limited480.0512.252.62%

Solara Active Pharma Sciences Ltd. Corporate Events

Solara Tightens KYC Norms for Physical Shareholders Under SEBI Mandate

Sep 26, 2026

Solara Active Pharma Sciences Ltd., a listed pharmaceutical company specializing in active pharmaceutical ingredients, is tightening compliance for investors who still hold shares in physical form. The move reflects broader regulatory efforts in Indi...

Solara Active Pharma Files Sustainability Report for FY 2025-26

Aug 25, 2026

Solara Active Pharma Sciences Limited has submitted its Business Responsibility and Sustainability Report for the 2025-26 financial year, covering operations from April 1, 2025 to March 31, 2026. The report is filed under SEBI’s listing regulations a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 08, 2026